Would you recommend the following article to a politician, an athlete, a business executive, or a scientist?

Inhibitex Outstrips Mixed Biotech Stocks Inhibitex Inc. stood out from a mixed biotechnology sector Monday, jumping more than 20 percent on news that it will receive a fast-tracked review for a staph-infection treatment.
